Xencor Stock Price, News & Analysis

Xencor, Inc. (NASDAQ:XNCR) has announced a research collaboration and license agreement with Janssen Biotech. This partnership focuses on developing XmAb bispecific antibodies targeting CD28 and a prostate tumor, aimed at treating prostate cancer. Xencor will receive an upfront payment of $50 million and potential future milestone payments and royalties on sales. Both companies will explore combination therapies using their respective drug candidate portfolios. The agreement is pending customary closing conditions, with expected completion by year-end.

Xencor, Inc. (NASDAQ:XNCR) reported updated data from a Phase 1 study of vibecotamab (XmAb®14045), a bispecific antibody targeting CD123 and CD3 in patients with relapsed or refractory acute myeloid leukemia (AML). Presenting at the 62nd ASH Annual Meeting, the results showed a 15% overall response rate with durable responses in some patients. The most common toxicity was mild-to-moderate cytokine release syndrome (CRS), affecting 61% of participants. Xencor's next steps include further development of vibecotamab, particularly in patient populations with minimal residual disease.

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company, will participate in three major conferences. The Jefferies Virtual London Healthcare Conference is scheduled for November 17-19, 2020, with a presentation on November 19 at 5:00 p.m. GMT. The SVB Leerink Oncology Day will occur on the same day. Additionally, the Piper Sandler 32nd Annual Virtual Healthcare Conference is set for November 30 - December 3, 2020, with presentation availability starting on November 23. Webcasts will be available on Xencor's website after the events.

Xencor (NASDAQ: XNCR) has entered a clinical collaboration with MorphoSys AG and Incyte to evaluate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma.

This partnership aims to accelerate the clinical development of plamotamab, which has shown promise in treating non-Hodgkin lymphoma. The Phase 1/2 study will be conducted in North America, Europe, and Asia-Pacific.

Xencor, Inc. (NASDAQ:XNCR) has presented new data from its preclinical XmAb bispecific antibody and IL-12-Fc cytokine programs at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). This includes advancements in CD28 bispecific antibodies designed to co-stimulate T cells targeting tumor cells. The company showcased two selective TGFβ inhibitors and IL-12-Fc fusions, showing improved anti-tumor activity and potential benefits over existing therapies. Xencor continues to advance its innovative monoclonal antibody technology aimed at treating cancer and autoimmune diseases.

Xencor, Inc. (NASDAQ:XNCR) announced that data from its Phase 1 dose-escalation study of vibecotamab will be presented at the 2020 ASH Annual Meeting. Vibecotamab is a bispecific antibody targeting CD123 and CD3, developed for treating relapsed/refractory acute myeloid leukemia (AML). Initial results indicate that patients with low disease burden and specific T-cell signatures may respond better to treatment. Toxicities were primarily mild-to-moderate, with cytokine release syndrome observed in 58% of patients. The study continues to optimize dosing and prepare for future trials.

Xencor, Inc. (NASDAQ: XNCR) will announce its third quarter 2020 financial results on November 5, 2020, after market close. Management will host a webcast and conference call at 4:30 p.m. ET to discuss these results and provide a corporate update. Investors can access the call via phone or through the company’s website. Xencor focuses on developing engineered monoclonal antibodies targeting cancer and autoimmune diseases, with 18 candidates currently in clinical development leveraging its proprietary XmAb® technology.

Xencor, Inc. (NASDAQ:XNCR) has announced four poster presentations at the virtual 35th Annual Meeting of the Society for Immunotherapy of Cancer, scheduled for November 9-14, 2020. The presentations will showcase updated results from the Phase 1 study of XmAb®20717, a PD-1 x CTLA-4 bispecific antibody targeting advanced solid tumors. New data on three preclinical-stage programs will also be presented. The poster session will occur from November 11-14, with access to the materials available via Xencor's website.

Xencor, Inc. (NASDAQ:XNCR) announced initial data from its ongoing Phase 1 study of tidutamab (XmAb®18087), a bispecific antibody targeting neuroendocrine tumors (NETs). Presented at the NANETS 2020 symposium, the preliminary results indicate that tidutamab was well-tolerated, showing dose-dependent T-cell proliferation. The study involved 27 patients with various NETs, achieving a disease control rate of 43%. Xencor plans further studies in Merkel cell carcinoma and small cell lung cancer, emphasizing tidutamab's promising safety profile and potential efficacy in solid tumors.